Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract

Since December 2019, a pandemic of COVID-19 disease, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly spread across the globe. At present, the Food and Drug Administration (FDA) has issued emergency approval for the use of some antiviral drugs. However, these d...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yuan, Almazi, Juhura G., Ong, Hui Xin, Johansen, Matt D., Ledger, Scott, Traini, Daniela, Hansbro, Philip M., Kelleher, Anthony D., Ahlenstiel, Chantelle L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909959/
https://www.ncbi.nlm.nih.gov/pubmed/35269550
http://dx.doi.org/10.3390/ijms23052408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909959/
https://www.ncbi.nlm.nih.gov/pubmed/35269550
http://dx.doi.org/10.3390/ijms23052408

Ejemplares similares